Apimeds Pharmaceuticals US (APUS) vs Ensysce Biosciences (ENSC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ensysce Biosciences is the larger company by market cap ($8.9 million vs $8.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APUS | ENSC |
|---|---|---|
| Share price | $5.51 | $0.458 |
| Market cap | $8.32M | $8.91M |
| 1-day change | -21.84% | +6.66% |
| YTD return | -66.40% | — |
| 1-year return | -70.53% | — |
| EPS (TTM) | $-36.03 | $-2.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $59.70 | $2.75 |
| 52-week low | $1.51 | $0.23 |
| Distance from 52-week high | -90.77% | -83.35% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1701.31% |
| Average volume | 3.66M | 14.21M |
| Shares outstanding | 1.51M | 19.46M |
| Employees | — | 8 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apimeds Pharmaceuticals US
APUS stock →Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure.
Healthcare · Drug Manufacturers - Specialty & Generic
About Ensysce Biosciences
ENSC stock →Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Healthcare · Biotechnology · 8 employees
APUS vs ENSC FAQ
Which is bigger, Apimeds Pharmaceuticals US or Ensysce Biosciences?
Ensysce Biosciences (ENSC) is larger, with a market capitalization of $8.91M compared with $8.32M for Apimeds Pharmaceuticals US (APUS).
Are Apimeds Pharmaceuticals US and Ensysce Biosciences in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Apimeds Pharmaceuticals US and Biotechnology for Ensysce Biosciences.